Continued increases in utilization of glucagon-like peptide-1 agonists (GLP-1s) are exerting pressure on healthcare cost trends and budgets, prompting a critical need for data-driven strategies to manage this growing financial strain. This white paper presents a quantitative analysis of GLP-1 utilization and cost, with a particular emphasis on anti-diabetic indicated GLP-1s in a sample of Medicaid managed care programs. We address the following questions:
- How does Medicaid preferred drug strategy impact GLP-1 utilization and spending on a gross and net cost basis?
- What does emerging experience tell us about future utilization?
- Does emerging experience show medical or pharmacy cost offsets for GLP-1 users?
